Showing results (161-170 of 333) with videos related to
Sort By:
Pageof 34
Lung Cancer (Amsterdam, Netherlands)|February 24, 2015
Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signalYosuke Togashi, Hidetoshi Hayashi, Kunio Okamoto, et al.European Journal of Cancer (Oxford, England : 1990)|March 28, 2026
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)Hiroaki Kanemura, Junko Tanizaki, Koji Matsumoto, et al.International Journal of Clinical Oncology|July 7, 2026
Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancerYusuke Kawanaka, Chiaki Inagaki, Masaki Okura, et al.Msphere|May 19, 2025
<i>Mycobacterium tuberculosis</i> bacillus induces pyroptosis in human lung fibroblastsTakemasa Takii, Hiroyuki Yamada, Chihiro Motozono, et al.Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.FEBS Letters|May 3, 2005
Transcriptional induction of Smurf2 ubiquitin ligase by TGF-betaNaro Ohashi, Tatsuo Yamamoto, Chiharu Uchida, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2017
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with NivolumabJunko Tanizaki, Koji Haratani, Hidetoshi Hayashi, et al.Cancer Science|October 2, 2012
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumorHidetoshi Hayashi, Takayasu Kurata, Yasuhito Fujisaka, et al.JTO Clinical and Research Reports|September 30, 2021
Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 StudyHiroaki Akamatsu, Shunsuke Teraoka, Hidetoshi Hayashi, et al.Lung Cancer (Amsterdam, Netherlands)|November 8, 2022
Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysisKohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, et al.Pageof 34